Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00513474 · ClinicalTrials.gov registry record · Phase 1
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT00513474: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00513474 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00513474, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
RATIONALE: Rasburicase may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying how well rasburicase works in preventing graft-versus-host disease in patients with hematologic cancer or other disease undergoing donor stem cell transplant.
Interventions
- DRUG cyclophosphamide
- DRUG etoposide
- DRUG methotrexate
- DRUG busulfan
- DRUG cyclosporin-A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2008-01 |
| Est. Completion | 2013-02-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00513474
The ClinicalTrials.gov registry entry for NCT00513474 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00513474 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00513474 about?
NCT00513474 is a clinical study titled "Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant". RATIONALE: Rasburicase may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying how well rasburicase works in preventing graft-versus-host disease in patients with hematologic cancer or other disease undergoing dono...
What is the current status of trial NCT00513474?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2008-01. Estimated completion is 2013-02-12.
What interventions are being tested in trial NCT00513474?
The interventions under investigation include: cyclophosphamide (DRUG), etoposide (DRUG), methotrexate (DRUG), busulfan (DRUG), cyclosporin-A (DRUG).
Who is sponsoring clinical trial NCT00513474?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.